Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | IL2 | P60568 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002079 | 0.89 | KDM4E (0.41) | LMNAMAPTHTTKDM4E | |
| SCHEMBL19002100 | 0.84 | NPC1 (0.45) | HTTKDM4EATM | |
| SCHEMBL23748196 | 0.83 | MAPT (0.42) | LMNAMAPTHTTKDM4EATM | |
| SCHEMBL2150715 | 0.75 | KDM4E (0.44) | LMNAMAPTHTTKDM4E | |
| SCHEMBL9607174 | 0.75 | KDM4E (0.42) | MAPTKDM4E | |
| SCHEMBL10442169 | 0.75 | ATM (0.45) | LMNAMAPTHTTKDM4EATM | |
| SCHEMBL7474680 | 0.75 | LMNA (0.55) | LMNAMAPTHTTKDM4EIL2 | |
| SCHEMBL8622918 | 0.75 | HTT (0.47) | LMNAMAPTHTTKDM4EATM | |
| SCHEMBL9607486 | 0.74 | ATM (0.46) | LMNAMAPTHTTKDM4EATM | |
| SCHEMBL10969020 | 0.74 | KDM4E (0.38) | LMNAMAPTHTTKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190151305-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2019-05-23 | — | — | US | disclosed |
| WO-2017103615-A1 | COMBINATION PRODUCT | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799494-B2 | Combination of respiratory electron transport chain inhibitors with a cytochrome bd inhibitor | NDUFB7, NDUFB3, NDUFB5 | LMNA 3846/4885MAPT 1315/4885HTT 3353/4885 |
| US-20190151305-A1 | COMBINATION PRODUCT | NDUFB5, NDUFB7, NDUFB10 | LMNA 3756/4885MAPT 1113/4885HTT 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.